Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Scleroproteins – e.g. – fibroin – elastin – silk – etc.
Reexamination Certificate
2005-03-29
2010-11-23
Kam, Chih-Min (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Scleroproteins, e.g., fibroin, elastin, silk, etc.
C623S013170, C623S014120, C606S214000
Reexamination Certificate
active
07838630
ABSTRACT:
The invention provides composition and methods for repairing a ruptured anterior cruciate ligament.
REFERENCES:
patent: 4186448 (1980-02-01), Brekke
patent: 4458678 (1984-07-01), Yannas et al.
patent: 4578067 (1986-03-01), Cruz
patent: 4808570 (1989-02-01), Michaeli
patent: 4846835 (1989-07-01), Grande
patent: 4955893 (1990-09-01), Yannas et al.
patent: 5171273 (1992-12-01), Silver et al.
patent: 5206023 (1993-04-01), Hunziker
patent: 5556429 (1996-09-01), Felt
patent: 5655546 (1997-08-01), Halpern
patent: 5681353 (1997-10-01), Li et al.
patent: 5713374 (1998-02-01), Pachence et al.
patent: 5749895 (1998-05-01), Sawyer et al.
patent: 5902741 (1999-05-01), Purchio et al.
patent: 6080192 (2000-06-01), Demopulos et al.
patent: 6087113 (2000-07-01), Caplan et al.
patent: 6096309 (2000-08-01), Prior et al.
patent: 6117425 (2000-09-01), MacPhee et al.
patent: 6129757 (2000-10-01), Weadock
patent: 6153292 (2000-11-01), Bell et al.
patent: 6171610 (2001-01-01), Vacanti et al.
patent: 6176880 (2001-01-01), Plouhar et al.
patent: 6365149 (2002-04-01), Vyakarnam et al.
patent: 6472210 (2002-10-01), Holy et al.
patent: 6629997 (2003-10-01), Mansmann et al.
patent: 6946003 (2005-09-01), Wolowacz et al.
patent: 6964685 (2005-11-01), Murray et al.
patent: 6989034 (2006-01-01), Hammer et al.
patent: 2002/0022884 (2002-02-01), Mansmann
patent: 2002/0183845 (2002-12-01), Mansmann et al.
patent: 2003/0147935 (2003-08-01), Binette et al.
patent: 2004/0059416 (2004-03-01), Murray et al.
patent: 2004/0267362 (2004-12-01), Hwang et al.
patent: 2005/0027307 (2005-02-01), Schwartz et al.
patent: 2005/0183731 (2005-08-01), Hunter et al.
patent: 0295721 (1988-12-01), None
patent: WO 85/00511 (1985-02-01), None
patent: WO 8500511 (1985-02-01), None
patent: WO 9213565 (1992-08-01), None
patent: WO 9321857 (1993-11-01), None
patent: WO 9525550 (1995-09-01), None
patent: WO 99/40771 (1999-08-01), None
patent: WO 02/067812 (2002-09-01), None
patent: WO 2004/078134 (2004-09-01), None
patent: WO 2004/078134 (2004-09-01), None
PCT International Search Report, PCT/US 07/01908, mail date Oct. 31, 2007.
PCT International Preliminary Report on Patentability, PCT/US2004/006392, issued Sep. 9, 2005.
PCT International Search Report, PCT/US2004/006392; mail date Feb. 21, 2005.
PCT International Preliminary Examination Report; PCT/US02/23885; completion date Mar. 5, 2004.
PCT International Search Report, PCT/US2002/023885; mail date Apr. 4, 2003.
Anseth et al., “Polymerizable degradable plyanhydrides with osteocompatibility,” 17(2)Nature Biotechnol. 156-159 (Feb. 1999).
Arendt and Dick, “Knee injury patterns among men and women in collegiate basketball and soccer,” 23(6)Am. J. Sports Med. 694-701 (1995).
Buck, “Regeneration of Tendon,” 66(1)J. Pathol. Bacteriol. 1-18 (1953).
Chamberlain et al., “Early peripheral nerve healing in collagen and silicone tube implants: myofibroblasts and the cellular response,” 19Biomaterials1393-1403 (1998).
Chamberlain, “Collagen-GAG Substrate Enhances the Quality of Nerve Regeneration through Collagen Tubes up to Level of Autograft,” 154(2)Experimental Neurology315-329 (Dec. 1998).
Chamberlain, “Long term functional and morphological evaluation of peripheral nerves regenerated through degradable collagen implants,” (M.S. Thesis, Massachusetts Institute of Technology, 1998) (copy on file with the MIT library).
Deie et al., “High intrinsic healing potential of human anterior cruciate ligament,” 66(1)Acta. Orthop. Scand. 28-32 (1995).
Desrosiers et al., “Proliferative and matrix synthesis response of canine anterior cruciate ligament fibroblasts submitted to combined growth factors,” 14(2)J. Orthop. Res. 200-208 (1996).
Draft guidance document for the preparation of free market notification [510(K)] Applications for Orthopedic Devices, U.S. Food and Drug Administration (Jul. 16, 1997).
Dye, “The Future Of Anterior Cruciate Ligament Restoration,” 325CLIN. Orthop. 130-139 (1996).
Faryniarz, et al., “Myofibroblasts in the healing lapine medial collateral ligament: possible mechanisms of contraction,” 14(2)J. Orthop. Res. 228-237 (1996).
Ferber, “Lab Grown Organs Take Shape,” 284(5413)Science422-425 (Apr. 16, 1999).
Ferber, “Tissue Engineering: From the Lab to the Clinic,” 284(5413)Science422-425 (Apr. 16, 1999).
Ford et al., “Autologous Collagen Vocal Fold Injection: A Preliminary Clinical Study,” 105Laryngoscope944-948 (Sep. 1995).
Frank et al., “Natural History of Healing in the Repaired Medical Collateral Ligament,” 1(2)J. Orthop. Res.179-188 (1983).
Geiger et al., “An in vitro assay of anterior cruciate ligament (ACL) and medial collateral ligament (MCL) cell migration,” 30(3)Connect Tissue Res. 215-224 (1994).
Gerich et al., “Gene transfer to the patellar tendon,”Knee Surg, Sports Traumatol, Arthroscopy(1997) 5:118-123.
Guidance document for testing biodegradable polymer implant devices, Division of General and Restorative Devices, Center for Devices and Radiological Health, U.S. Food and Drug Administration (Apr. 20, 1996).
Gwinn et al., “Relative general incidence of anterior cruciate ligament injury at a military service academy,” 66thAnnual Meeting of Amer. Acad. of Orthop. Surg., Anaheim, California (1999).
Hefti et al., “Healing of the Transected Anterior Cruciate Ligament in the Rabbit,” 73A (3)J. Bone Joint Surg. 373-383 (Mar. 1991).
International Search Report from International Application No. PCT/US02/23885, filed Jul. 29, 2002.
Jackson et al., “Biologic remodeling after anterior cruciate ligament reconstruction using a collagen matrix derived from demineralized bone: an experimental study in the goat model,” 24(4)Am. J. Sports Med. 405-414 (Jul.-Aug. 1996).
Kato et al., “Formation of continuous collagen fibres: evaluation of biocompatibility and mechanical properties,” 11Biomaterials169-175 (Apr. 1990).
Kawamoto et al., “Selective migration of alpha-smooth muscle actin-positive myofibroblasts toward fibronectin in the Boyden's blindwell chamber,” 93(4)Clin. Sci. 355-362 (1997).
Louie, “Effect of a porous collagen-glycosaminoglycan copolymer on early tendon healing in a novel animal model,” (Ph.D. Thesis, Massachusetts Institute of Technology, 1997) (copy on file with the MIT Library).
Louie, L. K. et al., “Healing of tendon defects implanted with a porous collagen-GAG matrix: histological evaluation,” 3(2)Tissue Eng 'g187-195 (1997).
Louie, L. K., et al., “Development of a collagen-GAG copolymer implant for the study of tendon regeneration,” M331Mat. Res. Soc. Symp. Proc. 19-24 (1994).
Marshall et al., “The Anterior Cruciate Ligament: A Technique of Repair and Reconstruction,” 143Clin. Orthop. 97-106 (Sep. 1979).
Masur et al., “Myofibroblasts differentiate from fibroblasts when plated at low density,” 93(9)Proc. Nat'l Acad. Sci. USA4219-4223 (Apr. 1996).
Murray et al., “Differences in the outgrowth of cells from explants from the proximal and distal human ACL and response to TGF-B1,” Transactions of the 47thAnnual Meeting of the Orthopaedic Research Society, Feb. 25-28, 2001; San Francisco, CA.
Murray et al., “Fibroblast distribution in the anteriomedial bundle of the human anterior cruciate ligament: The presence of alpha smooth muscle actin-positive cells,” 17(1)J. Orthop. Res. 18-27 (1999).
Murray et al., “Histological changes in the human anterior cruciate ligament after rupture,” 82A(10)J. Bone Joint Surg. 1387-1397 (2000).
Murray et al., “Migration of cells from human anterior cruciate ligament explants into collagen-glycosaminoglycan scaffolds,” 18(4)J. Orthop. Res. 557-564 (2000).
Murray et al., “Migration of cells from ruptured human anterior cruciate ligament explants into collagen-GAG matrices,” Proceedings of the Sixth World Biomaterials
Marler Jennifer
Murray Martha M.
Murray Michael F.
Children's Medical Center Corporation
Kam Chih-Min
Nixon & Peabody LLP
LandOfFree
Biologic replacement for fibrin clot does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biologic replacement for fibrin clot, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biologic replacement for fibrin clot will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4246994